A tumor-specific HLA-bound neoantigenic peptide encoded by EWSR1::FLI1-induced neogenes
Tumor-specific neoantigenic peptides encoded by EWSR1::FLI1-induced neogenes provide a targeted immune response for Ewing sarcoma treatment, enhancing treatment efficacy while minimizing autoimmune risks.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- INSTITUT CURIE
- Filing Date
- 2026-01-16
- Publication Date
- 2026-07-23
AI Technical Summary
Current treatments for Ewing sarcoma are ineffective due to low immunogenicity and immune tolerance, with a 5-year survival rate of only 30% for metastatic cases, and there is a lack of identified tumor-specific HLA-bound neoantigenic peptides encoded by EWSR1::FLI1-induced neogenes for targeted immune response.
Identification and utilization of tumor-specific neoantigenic peptides encoded by EWSR1::FLI1-induced neogenes, which are expressed in Ewing sarcoma cells but not healthy cells, to develop vaccines and immunotherapies that activate CD8 T cells to specifically target and kill tumor cells.
The peptides enable targeted immune responses against Ewing sarcoma, potentially increasing treatment efficacy and reducing autoimmune risks, as demonstrated by CD8 T cells' ability to recognize and kill Ewing sarcoma cells in an HLA-restricted manner.
Smart Images

Figure IMGF000027_0001 
Figure IMGF000016_0001_TABLE 
Figure IMGF000051_0001_TABLE